Reversing malignant cancer cells to a normal state
A new proof-of-principle study demonstrates the DCAF5 protein is a promising target, which could avoid the need for toxic therapies.
List view / Grid view
A new proof-of-principle study demonstrates the DCAF5 protein is a promising target, which could avoid the need for toxic therapies.
The findings from DNA and RNA sequencing in primary and metastatic UTUC tumours could lead to strategies to improve patient outcomes.
A new study proves that organoid drug testing is highly accurate at predicting effective treatments and finds a novel therapeutic option.
Researchers suggest that DA histology slowly emerges by accumulating burdens of DNA damage and copy number aberrations.
Researchers discover that blocking PD-L2 in senescent cells increases the efficacy of chemotherapy in mouse models.
The ML algorithm explores how genetic mutations collectively influence a tumour’s reaction to drugs impeding DNA replication.
In this Q&A, Dr Lev Becker, Associate Professor, University of Chicago and Cofounder of Onchilles Pharma, reveals how his company is directing research into neutrophil biology to the advantage of cancer patients that need it most.
Novel self-assembled amino acid-based nanoparticles, loaded with doxorubicin, could evolve cancer treatment.
Glioblastomas can resist immunotherapy as perivascular fibroblasts support the creation of an immunosuppressive tumour environment.
Our inaugural report is an exploration of the remarkable advancements in cancer research and the field of drug discovery.
Combining cancerous and non-cancerous cell patterns, the AI model evaluates breast cancer outcomes better than expert pathologists.
Understanding more about the effect of liposome nanoparticles on the immune system will improve drug delivery systems.
Lactate producing bacteria is responsible for rewiring metabolic signalling pathways, causing resistance to radiation therapy.
US researchers innovate cancer diagnostics using Kinase Inhibitor Pulldown Assay, or KIPA, to search for proteins they could target to control tumour growth.
A combination of radiotherapy followed by immunotherapy is a promising strategy for the treatment of oral malignant melanomas in dogs.